Fostamatinib Disodium Patent Expiration
Fostamatinib Disodium is Used for treating thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who had an insufficient response to previous treatment. It was first introduced by Rigel Pharmaceuticals Inc
Fostamatinib Disodium Patents
Given below is the list of patents protecting Fostamatinib Disodium, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Tavalisse | US8771648 | (Trimethoxyphenylamino) pyrimidinyl formulations | Jul 27, 2032 | Rigel Pharms |
| Tavalisse | US8951504 | (trimethoxyphenylamino) pyrimidinyl formulations | Jul 27, 2032 | Rigel Pharms |
| Tavalisse | US7449458 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses | Sep 04, 2031 | Rigel Pharms |
| Tavalisse | US8263122 | Wet granulation using a water sequestering agent | Nov 24, 2030 | Rigel Pharms |
| Tavalisse | US8652492 | Wet granulation using a water sequestering agent | Nov 06, 2028 | Rigel Pharms |
| Tavalisse | US8163902 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses | Jun 17, 2026 | Rigel Pharms |
| Tavalisse | US8445485 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses | Jun 17, 2026 | Rigel Pharms |
| Tavalisse | US8912170 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses | Jun 17, 2026 | Rigel Pharms |
| Tavalisse | US9283238 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses | Jun 17, 2026 | Rigel Pharms |
| Tavalisse | US7989448 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses | Jun 12, 2026 | Rigel Pharms |
| Tavalisse | US7538108 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses | Mar 28, 2026 | Rigel Pharms |
| Tavalisse | US8211889 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses | Jan 19, 2026 | Rigel Pharms |
| Tavalisse | US9266912 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses | Jan 19, 2026 | Rigel Pharms |
| Tavalisse | US9737554 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses | Jan 19, 2026 | Rigel Pharms |
| Tavalisse | USRE48898 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses | Jan 19, 2026 | Rigel Pharms |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Fostamatinib Disodium's patents.
Latest Legal Activities on Fostamatinib Disodium's Patents
Given below is the list recent legal activities going on the following patents of Fostamatinib Disodium.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Petition Decision - Accept Late Payment of Maintenance Fees - Granted Critical
| 07 May, 2024 | US9283238 |
| Mail-Petition Decision - Accept Late Payment of Maintenance Fees - Granted Critical
| 07 May, 2024 | US9283238 |
| Petition to Accept Late Payment of Maintenance Fee Payment Filed Critical
| 07 May, 2024 | US9283238 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 07 May, 2024 | US9283238 |
| Surcharge, Petition to Accept Pymt After Exp, Unintentional. | 07 May, 2024 | US9283238 |
| Expire Patent Critical
| 22 Apr, 2024 | US9283238 |
| Payment of Maintenance Fee, 12th Yr, Small Entity | 11 Mar, 2024 | US8263122 |
| Change in Power of Attorney (May Include Associate POA) Critical
| 28 Feb, 2024 | US8771648 |
| Email Notification Critical
| 28 Feb, 2024 | US8652492 |
| Email Notification Critical
| 28 Feb, 2024 | US8771648 |
Fostamatinib Disodium's Family Patents
